Modified R-CODOX-M/IVAC Chemotherapy Regimens in Chinese Patients with Untreated Sporadic Burkitt Lymphoma

Overview

Journal Cancer Biol Med

Specialty Oncology

Date 2022 Aug 18

PMID 35979854

Authors

Meiting Chen

Zhao Wang

Xiaojie Fang

Yuyi Yao

Quanguang Ren

Zegeng Chen

Ying Tian

Fei Pan

Xiaoqian Li

Zhiming Li

Qingqing Cai

He Huang

Tongyu Lin

Affiliations

Soon will be listed here.

Abstract

Objective: To characterize modified R-CODOX-M/IVAC-based chemotherapy to lower the severe adverse events in Chinese adult patients with sporadic Burkitt lymphoma.

Methods: We enrolled a retrospective cohort including 123 adult patients with untreated sporadic Burkitt lymphoma from August 2008 to September 2019 at Sun Yat-sen University Cancer Center. We studied a dose-modified and long-course R-CODOX-M/IVAC regimen utilizing a low dose of 1.0 g/m/cycle cyclophosphamide, 2 g/m/cycle methotrexate, 4,500 mg/m/cycle ifosfamide, and 4.0 g/m/cycle cytarabine. Forty-nine patients with low risk disease underwent 4-6 cycles of dose-modified R-CODOX-M-based chemotherapy. Seventy-four patients with high risk disease underwent 6-8 cycles of dose-modified alternating R-CODOX-M/IVAC regimens.

Results: The objective remission was 87.0%. The event-free survival rate and overall survival at 3 years were 81.2% and 92.1%, respectively. Major grade 3-4 adverse events included leukopenia (91.9%), anemia (58.5%), thrombocytopenia (73.2%), and febrile neutropenia (48.8%). A total of 26.0% and 37.4% of patients received red blood cell and platelet transfusions, respectively. We observed 4 cases (3.3%) of septic shock after chemotherapy. Two treatment-related deaths occurred from severe infection.

Conclusions: The modified R-CODOX-M/IVAC chemotherapy regimen was effective for sporadic Burkitt lymphoma in the Chinese population, with a lower toxicity than standard regimens.

Citing Articles

Prognostic Factors for Survival in Adults With Burkitt Lymphoma: A Systematic Review.

de Armas-Castellano A, Infante-Ventura D, Del Pino-Sedeno T, Hernandez Y, Quiros R, Leon-Salas B Cancer Med. 2025; 14(3):e70513.

PMID: 39878399 PMC: 11775923. DOI: 10.1002/cam4.70513.

Tumor microenvironment as a complex milieu driving cancer progression: a mini review.

Li Z, Li J, Bai X, Huang X, Wang Q Clin Transl Oncol. 2024; .

PMID: 39342061 DOI: 10.1007/s12094-024-03697-w.

Blocking MyD88 signaling with MyD88 inhibitor prevents colitis-associated colorectal cancer development by maintaining colonic microbiota homeostasis.

Xie B, Wang B, Shang R, Wang L, Huang X, Xie L Sci Rep. 2023; 13(1):22552.

PMID: 38110638 PMC: 10728211. DOI: 10.1038/s41598-023-49457-8.

Comparison of chemotherapy regimens plus rituximab in adult Burkitt lymphoma: A single-arm meta-analysis.

Lu X, Liu Y, Liu R, Liu J, Yan X, Qian L Front Oncol. 2023; 12:1063689.

PMID: 36620579 PMC: 9816660. DOI: 10.3389/fonc.2022.1063689.

Nomogram for prognosis of patients with esophageal squamous cell cancer after minimally invasive esophagectomy established based on non-textbook outcome.

Xu S, Lin L, Chen T, You C, Chen C, Chen R Surg Endosc. 2022; 36(11):8326-8339.

PMID: 35556169 DOI: 10.1007/s00464-022-09290-y.

References

Lacasce A, Howard O, Lib S, Fisher D, Weng A, Neuberg D . Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma. 2004; 45(4):761-7. DOI: 10.1080/1042819031000141301. View

Yang X, Huang Q, Li A, Chen Y, Xu W, Li J . A long-term retrospective study on sporadic Burkitt lymphoma in chinese population. Medicine (Baltimore). 2020; 99(5):e18438. PMC: 7004692. DOI: 10.1097/MD.0000000000018438. View

. Chinese guidelines for diagnosis and treatment of malignant lymphoma 2018 (English version). Chin J Cancer Res. 2019; 31(4):557-577. PMC: 6736656. DOI: 10.21147/j.issn.1000-9604.2019.04.01. View

Zuze T, Ellis G, Kasonkanji E, Kaimila B, Nyasosela R, Nyirenda R . Modified EPOCH for high-risk non-Hodgkin lymphoma in sub-Saharan Africa. Cancer Med. 2019; 9(1):77-83. PMC: 6943163. DOI: 10.1002/cam4.2631. View

Cheson B, Fisher R, Barrington S, Cavalli F, Schwartz L, Zucca E . Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014; 32(27):3059-68. PMC: 4979083. DOI: 10.1200/JCO.2013.54.8800. View

Mead G, Sydes M, Walewski J, Grigg A, Hatton C, Pescosta N . An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol. 2002; 13(8):1264-74. DOI: 10.1093/annonc/mdf253. View

Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G . RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma. Br J Haematol. 2011; 156(2):234-44. DOI: 10.1111/j.1365-2141.2011.08947.x. View

Ribrag V, Koscielny S, Bosq J, Leguay T, Casasnovas O, Fornecker L . Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10036):2402-11. DOI: 10.1016/S0140-6736(15)01317-3. View

Jacobson C, LaCasce A . How I treat Burkitt lymphoma in adults. Blood. 2014; 124(19):2913-20. DOI: 10.1182/blood-2014-06-538504. View

10.

Mead G, Barrans S, Qian W, Walewski J, Radford J, Wolf M . A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood. 2008; 112(6):2248-60. PMC: 2532802. DOI: 10.1182/blood-2008-03-145128. View

11.

Rizzieri D, Johnson J, Byrd J, Lozanski G, Blum K, Powell B . Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol. 2014; 165(1):102-11. PMC: 3996561. DOI: 10.1111/bjh.12736. View

12.

Casulo C, Friedberg J . Treating Burkitt Lymphoma in Adults. Curr Hematol Malig Rep. 2015; 10(3):266-71. DOI: 10.1007/s11899-015-0263-4. View

13.

Ye Z, Xiao Y, Shi H, Ke Z, Liu Y, Liang Y . Sporadic Burkitt lymphoma in southern China: 12 years' experience in a single institution in Guangzhou. J Clin Pathol. 2011; 64(12):1132-5. DOI: 10.1136/jclinpath-2011-200118. View

14.

Rizzieri D, Johnson J, Niedzwiecki D, Lee E, Vardiman J, Powell B . Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. Cancer. 2004; 100(7):1438-48. DOI: 10.1002/cncr.20143. View

15.

Magrath I, Adde M, Shad A, Venzon D, Seibel N, Gootenberg J . Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol. 1996; 14(3):925-34. DOI: 10.1200/JCO.1996.14.3.925. View

16.

Costa L, Xavier A, Wahlquist A, Hill E . Trends in survival of patients with Burkitt lymphoma/leukemia in the USA: an analysis of 3691 cases. Blood. 2013; 121(24):4861-6. PMC: 3682339. DOI: 10.1182/blood-2012-12-475558. View

17.

Noy A, Lee J, Cesarman E, Ambinder R, Baiocchi R, Reid E . AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma. Blood. 2015; 126(2):160-6. PMC: 4497960. DOI: 10.1182/blood-2015-01-623900. View

18.

Dunleavy K, Pittaluga S, Shovlin M, Steinberg S, Cole D, Grant C . Low-intensity therapy in adults with Burkitt's lymphoma. N Engl J Med. 2013; 369(20):1915-25. PMC: 3901044. DOI: 10.1056/NEJMoa1308392. View

19.

Evens A, Carson K, Kolesar J, Nabhan C, Helenowski I, Islam N . A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma. Ann Oncol. 2013; 24(12):3076-81. PMC: 3841019. DOI: 10.1093/annonc/mdt414. View